(Q37994309)

26 August 2017

Biomarkers for systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

26 August 2017

0 references

0 references

4

Susan Manzi

1 reference

26 August 2017

Joseph M Ahearn

1

1 reference

PubMed ID

22424435

26 August 2017

Chau-Ching Liu

series ordinal

2

1 reference

PubMed ID

22424435

26 August 2017

Amy H Kao

series ordinal

3

1 reference

26 August 2017

10 February 2012

1 reference

26 August 2017

Translational Research

1 reference

26 August 2017

159

1 reference

26 August 2017

4

1 reference

26 August 2017

326-342

1 reference

Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Genetically determined mannan-binding lectin deficiency is of minor importance in determining susceptibility to severe infections and vascular organ damage in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Current status of lupus genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Delineating the genetic basis of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Genetics of human systemic lupus erythematosus: the emerging picture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Significance of MHC class II haplotypes and IgG Fc receptors in SLE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Genetics of susceptibility and severity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

General aspects of the genetics of SLE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Systemic lupus erythematosus, complement deficiency, and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

The intricate role of complement component C4 in human systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

A comparison of the properties of two classes, C4A and C4B, of the human complement component C4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Determining the one, two, three, or four long and short loci of human complement C4 in a major histocompatibility complex haplotype encoding C4A or C4B proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

PTPN22: its role in SLE and autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Immune Interferon in the Circulation of Patients with Autoimmune Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

The genetics and biology of Irf5-mediated signaling in lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: support for a crucial role of intron 1 polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

STAT4: genetics, mechanisms, and implications for autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Predictive value of autoantibodies for activity of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Systemic lupus erythematosus serum deposits C4d on red blood cells, decreases red blood cell membrane deformability, and promotes nitric oxide production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Platelet C4d is highly specific for systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Fifty years of anti-ds DNA antibodies: are we approaching journey's end?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Significantly higher percentage of circulating CD27(high) plasma cells in systemic lupus erythematosus patients with infection than with disease flare-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Interferon-alpha in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

The type I interferon system in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Systemic lupus erythematosus: all roads lead to type I interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

The innate immune system in SLE: type I interferons and dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Synthesis and release of B-lymphocyte stimulator from myeloid cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

BAFF overexpression is associated with autoantibody production in autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Increased expression of ganglioside GM1 in peripheral CD4+ T cells correlates soluble form of CD30 in Systemic Lupus Erythematosus patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

MicroRNAs as biomarkers in rheumatic diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Biomarkers for lupus nephritis: the quest continues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Biomarkers for lupus nephritis: a critical appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Mathematical framework for human SLE Nephritis: disease dynamics and urine biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Complement component c1q and anti-c1q antibodies in theory and in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Antinucleosome antibodies as a marker of active proliferative lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Are anti-C1q antibodies different from other SLE autoantibodies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Urine chemokines as biomarkers of human systemic lupus erythematosus activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Urinary TWEAK and the activity of lupus nephritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

New insights into central nervous system lupus: a clinical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Cognition and immunity; antibody impairs memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Immunity and behavior: antibodies alter emotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Human lupus autoantibodies against NMDA receptors mediate cognitive impairment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

The impact of systems approaches on biological problems in drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Clinical proteomics: translating benchside promise into bedside reality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

Meta-analysis of genome-wide linkage studies of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.021

10.1016/J.TRSL.2012.01.021

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22424435